Kiora Pharmaceuticals (KPRX) Other Operating Expenses (2020 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Other Operating Expenses came in at -$1.2 million in Q1 2026, up 27.51% YoY from -$961352.3 in Q1 2025, and down 129.9% on a QoQ basis from $4.1 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Other Operating Expenses (2020 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 7 years of Other Operating Expenses data on file, last reported at -$1.2 million in Q1 2026.
- Quarterly Other Operating Expenses rose 27.51% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$73428.0 (down 254.66% YoY) and the FY2024 annual result came in at -$3859.0, up 86.4% from the prior year.
- Other Operating Expenses declined to -$1.2 million in Q1 2026, from $4.1 million in the prior quarter.
- In the past five years, Other Operating Expenses ranged from a high of $4.1 million in Q4 2025 to a low of -$2.3 million in Q3 2025.
- A 5-year average of $297637.6 and a median of $65332.5 in 2022 frame the typical range for Other Operating Expenses.
- Annual changes were most pronounced in 2023 — Other Operating Expenses soared 912.61% — and 2025, when it slumped 467.7%.
- Tracing KPRX's Other Operating Expenses over 5 years: stood at -$984576.0 in 2022, then soared by 112.84% to $126454.0 in 2023, then surged by 293.99% to $498212.0 in 2024, then surged by 722.84% to $4.1 million in 2025, then sank by 129.9% to -$1.2 million in 2026.
- The last three Other Operating Expenses figures came in at -$1.2 million (Q1 2026), $4.1 million (Q4 2025), and -$2.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Kiora Pharmaceuticals | 16.25 Mn | 16.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.25 Mn |
| Mar 31, 2026 | -1.23 Mn |
| Dec 31, 2025 | 4.10 Mn |
| Sep 30, 2025 | -2.31 Mn |
| Jun 30, 2025 | -640,633.00 |
| Mar 31, 2025 | -1.69 Mn |
| Dec 31, 2024 | 498,212.00 |
| Sep 30, 2024 | 1.35 Mn |
| Jun 30, 2024 | -112,847.00 |
| Mar 31, 2024 | 1.29 Mn |
| Dec 31, 2023 | 126,454.00 |
| Sep 30, 2023 | 3.42 Mn |
| Dec 31, 2022 | -984,576.00 |
| Sep 30, 2022 | 337,515.00 |
| Mar 31, 2022 | 4,211.00 |
| Dec 31, 2021 | 3.99 Mn |
| Sep 30, 2021 | 68,006.00 |
| Jun 30, 2021 | 73,717.00 |
| Mar 31, 2021 | -570,203.00 |
| Dec 31, 2020 | -1.34 Mn |